Aarons L - Search Results

1

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A. Darwich AS, et al. Among authors: aarons l. Clin Pharmacol Ther. 2017 May;101(5):646-656. doi: 10.1002/cpt.659. Epub 2017 Apr 4. Clin Pharmacol Ther. 2017. PMID: 28182269 Review.

2

Design of population pharmacokinetic experiments using prior information.

Ogungbenro K, Aarons L. Ogungbenro K, et al. Among authors: aarons l. Xenobiotica. 2007 Oct-Nov;37(10-11):1311-30. doi: 10.1080/00498250701553315. Xenobiotica. 2007. PMID: 17968747 Review.

3

Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach.

Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, Aarons L. Tsamandouras N, et al. Among authors: aarons l. Clin Pharmacol Ther. 2014 Jul;96(1):90-100. doi: 10.1038/clpt.2014.55. Epub 2014 Mar 5. Clin Pharmacol Ther. 2014. PMID: 24598718

4

Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity.

Ogungbenro K, Aarons L; CRESim & Epi-CRESim Project Groups. Ogungbenro K, et al. Among authors: aarons l. Br J Clin Pharmacol. 2015 Jul;80(1):86-100. doi: 10.1111/bcp.12588. Epub 2015 Jun 1. Br J Clin Pharmacol. 2015. PMID: 25614061 Free PMC article.

5

Evaluation of area under the concentration curve adjusted by the terminal-phase as a metric to reduce the impact of variability in bioequivalence testing.

Lucas AJ, Ogungbenro K, Yang S, Aarons L, Chen C. Lucas AJ, et al. Among authors: aarons l. Br J Clin Pharmacol. 2022 Feb;88(2):619-627. doi: 10.1111/bcp.14986. Epub 2021 Aug 24. Br J Clin Pharmacol. 2022. PMID: 34272747 Free article.

6

A "middle-out approach" for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models.

Yau E, Gertz M, Ogungbenro K, Aarons L, Olivares-Morales A. Yau E, et al. Among authors: aarons l. CPT Pharmacometrics Syst Pharmacol. 2023 Mar;12(3):346-359. doi: 10.1002/psp4.12915. Epub 2023 Jan 31. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36647756 Free PMC article.

7

Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children.

Cleary Y, Kletzl H, Grimsey P, Heinig K, Ogungbenro K, Silber Baumann HE, Frey N, Aarons L, Galetin A, Gertz M. Cleary Y, et al. Among authors: aarons l. Clin Pharmacokinet. 2023 Jun;62(6):891-904. doi: 10.1007/s40262-023-01241-7. Epub 2023 May 6. Clin Pharmacokinet. 2023. PMID: 37148485 Free PMC article.

8

Population pharmacokinetics: theory and practice.

Aarons L. Aarons L. Br J Clin Pharmacol. 1991 Dec;32(6):669-70. Br J Clin Pharmacol. 1991. PMID: 1768557 Free PMC article. No abstract available.

9

A note on the use of salicylate saliva concentration in clinical pharmacokinetic studies.

Khan AZ, Aarons L. Khan AZ, et al. Among authors: aarons l. J Pharm Pharmacol. 1989 Oct;41(10):710-1. doi: 10.1111/j.2042-7158.1989.tb06346.x. J Pharm Pharmacol. 1989. PMID: 2575150

10

Population pharmacokinetics of tobramycin.

Aarons L, Vozeh S, Wenk M, Weiss P, Follath F. Aarons L, et al. Br J Clin Pharmacol. 1989 Sep;28(3):305-14. doi: 10.1111/j.1365-2125.1989.tb05431.x. Br J Clin Pharmacol. 1989. PMID: 2789924 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters